Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E.
Animals
Antibodies, Neutralizing
/ immunology
Botulinum Toxins
/ chemistry
Botulinum Toxins, Type A
/ chemistry
Botulism
/ metabolism
CD8-Positive T-Lymphocytes
/ immunology
Catalytic Domain
/ genetics
Cloning, Molecular
/ methods
Clostridium botulinum
/ genetics
Humans
Immunization
Male
Mice
Mice, Inbred BALB C
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 08 2020
18 08 2020
Historique:
received:
20
01
2020
accepted:
21
07
2020
entrez:
20
8
2020
pubmed:
20
8
2020
medline:
8
1
2021
Statut:
epublish
Résumé
Botulinum neurotoxins (BoNTs) represent a family of bacterial toxins responsible for neuroparalytic disease 'botulism' in human and animals. Their potential use as biological weapon led to their classification in category 'A' biowarfare agent by Centers for Disease Control and Prevention (CDC), USA. In present study, gene encoding full length catalytic domain of BoNT/E-LC was cloned, expressed and protein was purified using Ni-NTA chromatography. Humoral immune response was confirmed by Ig isotyping and cell-mediated immunity by cytokine profiling and intracellular staining for enumeration of IFN-γ secreting CD4
Identifiants
pubmed: 32811892
doi: 10.1038/s41598-020-70929-8
pii: 10.1038/s41598-020-70929-8
pmc: PMC7434876
doi:
Substances chimiques
Antibodies, Neutralizing
0
Botulinum Toxins
EC 3.4.24.69
Botulinum Toxins, Type A
EC 3.4.24.69
botulinum toxin type E
T579M564JY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13932Références
Gill, D. M. Bacterial toxins: A table of lethal amounts. Microbiol. Rev. 46, 86–94 (1982).
doi: 10.1128/MMBR.46.1.86-94.1982
Turton, K., Chaddock, J. A. & Acharya, K. R. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 27, 552–558. https://doi.org/10.1016/s0968-0004(02)02177-1 (2002).
doi: 10.1016/s0968-0004(02)02177-1
pubmed: 12417130
Arnon, S. S. et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285, 1059–1070. https://doi.org/10.1001/jama.285.8.1059 (2001).
doi: 10.1001/jama.285.8.1059
pubmed: 11209178
Surana, S. et al. The travel diaries of tetanus and botulinum neurotoxins. Toxicon 147, 58–67. https://doi.org/10.1016/j.toxicon.2017.10.008 (2018).
doi: 10.1016/j.toxicon.2017.10.008
pubmed: 29031941
Johnson, E. A. & Bradshaw, M. Clostridium botulinum and its neurotoxins: A metabolic and cellular perspective. Toxicon 39, 1703–1722. https://doi.org/10.1016/s0041-0101(01)00157-x (2001).
doi: 10.1016/s0041-0101(01)00157-x
pubmed: 11595633
Barash, J. R. & Arnon, S. S. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 209, 183–191. https://doi.org/10.1093/infdis/jit449 (2014).
doi: 10.1093/infdis/jit449
pubmed: 24106296
Maslanka, S. E. et al. A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin. J. Infect. Dis. 213, 379–385. https://doi.org/10.1093/infdis/jiv327 (2016).
doi: 10.1093/infdis/jiv327
pubmed: 26068781
Kalb, S. R. et al. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal. Chem. 87, 3911–3917. https://doi.org/10.1021/ac504716v (2015).
doi: 10.1021/ac504716v
pubmed: 25731972
pmcid: 4522910
Schiavo, G., Matteoli, M. & Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717–766. https://doi.org/10.1152/physrev.2000.80.2.717 (2000).
doi: 10.1152/physrev.2000.80.2.717
pubmed: 10747206
Simpson, L. L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167–193. https://doi.org/10.1146/annurev.pharmtox.44.101802.121554 (2004).
doi: 10.1146/annurev.pharmtox.44.101802.121554
pubmed: 14744243
Schiavo, G. et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832–835. https://doi.org/10.1038/359832a0 (1992).
doi: 10.1038/359832a0
pubmed: 1331807
Singh, B. R. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox. Res. 9, 73–92. https://doi.org/10.1007/bf03033925 (2006).
doi: 10.1007/bf03033925
pubmed: 16785103
Kumaran, D. et al. Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation. J. Mol. Biol. 386, 233–245. https://doi.org/10.1016/j.jmb.2008.12.027 (2009).
doi: 10.1016/j.jmb.2008.12.027
pubmed: 19118561
Valipour, E., Moosavi, M. L., Amani, J. & Nazarian, S. High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E. World J. Microbiol. Biotechnol. 30, 1861–1867. https://doi.org/10.1007/s11274-014-1609-0 (2014).
doi: 10.1007/s11274-014-1609-0
pubmed: 24469548
CDC. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb. Mortal. Wkly. Rep. 59, 299 (2010).
Arnon, S. S., Schechter, R., Maslanka, S. E., Jewell, N. P. & Hatheway, C. L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 354, 462–471. https://doi.org/10.1056/NEJMoa051926 (2006).
doi: 10.1056/NEJMoa051926
pubmed: 16452558
Payne, J. R., Khouri, J. M., Jewell, N. P. & Arnon, S. S. Efficacy of human botulism immune globulin for the treatment of infant botulism: The first 12 years post licensure. J. Pediatr. 193, 172–177. https://doi.org/10.1016/j.jpeds.2017.10.035 (2018).
doi: 10.1016/j.jpeds.2017.10.035
pubmed: 29229452
CDC. Notice of CDC’s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR. Morbid. Mortal. Wkly Rep. 60, 1454–1455 (2011).
Webb, R. P. & Smith, L. A. What next for botulism vaccine development?. Expert Rev. Vaccines 12, 481–492. https://doi.org/10.1586/erv.13.37 (2013).
doi: 10.1586/erv.13.37
pubmed: 23659297
Pirazzini, M. & Rossetto, O. Challenges in searching for therapeutics against Botulinum Neurotoxins. Expert Opin. Drug Discov. 12, 497–510. https://doi.org/10.1080/17460441.2017.1303476 (2017).
doi: 10.1080/17460441.2017.1303476
pubmed: 28271909
Kondo, H., Kondo, S., Murata, R. & Sakaguchi, G. Antigenicity of Clostridium botulinum type-E formol toxoid. Jpn. J. Med. Sci. Biol. 22, 75–85. https://doi.org/10.7883/yoken1952.22.75 (1969).
doi: 10.7883/yoken1952.22.75
pubmed: 4899485
Smith, L. A. & Rusnak, J. M. Botulinum neurotoxin vaccines: Past, present, and future. Crit. Rev. Immunol. 27, 303–318. https://doi.org/10.1615/critrevimmunol.v27.i4.20 (2007).
doi: 10.1615/critrevimmunol.v27.i4.20
pubmed: 18197811
Smith, L. A. Botulism and vaccines for its prevention. Vaccine 27(Suppl 4), D33-39. https://doi.org/10.1016/j.vaccine.2009.08.059 (2009).
doi: 10.1016/j.vaccine.2009.08.059
pubmed: 19837283
Rusnak, J. M. & Smith, L. A. Botulinum neurotoxin vaccines: Past history and recent developments. Hum. Vaccines 5, 794–805. https://doi.org/10.4161/hv.9420 (2009).
doi: 10.4161/hv.9420
Sundeen, G. & Barbieri, J. T. Vaccines against Botulism. Toxins. https://doi.org/10.3390/toxins9090268 (2017).
doi: 10.3390/toxins9090268
pubmed: 28869493
pmcid: 5618201
Webb, R. P. Engineering of botulinum neurotoxins for biomedical applications. Toxins. https://doi.org/10.3390/toxins10060231 (2018).
doi: 10.3390/toxins10060231
pubmed: 29986427
pmcid: 6070791
Webb, R. P. et al. Recombinant botulinum neurotoxin Hc subunit (BoNT Hc) and catalytically inactive Clostridium botulinum holoproteins (ciBoNT HPs) as vaccine candidates for the prevention of botulism. Toxins. https://doi.org/10.3390/toxins9090269 (2017).
doi: 10.3390/toxins9090269
pubmed: 28869522
pmcid: 5618202
Przedpelski, A. et al. Enhancing toxin-based vaccines against botulism. Vaccine 36, 827–832. https://doi.org/10.1016/j.vaccine.2017.12.064 (2018).
doi: 10.1016/j.vaccine.2017.12.064
pubmed: 29307477
pmcid: 5820173
Webb, R. P., Smith, T. J., Wright, P., Brown, J. & Smith, L. A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27, 4490–4497. https://doi.org/10.1016/j.vaccine.2009.05.030 (2009).
doi: 10.1016/j.vaccine.2009.05.030
pubmed: 19450643
Webb, R. et al. Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF). Toxicon 176, 67–76. https://doi.org/10.1016/j.toxicon.2020.02.001 (2020).
doi: 10.1016/j.toxicon.2020.02.001
pubmed: 32032587
Baldwin, M. R. et al. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76, 1314–1318. https://doi.org/10.1128/iai.01025-07 (2008).
doi: 10.1128/iai.01025-07
pubmed: 18070903
Rasetti-Escargueil, C. et al. The European AntibotABE framework program and its update: Development of innovative botulinum antibodies. Toxins. https://doi.org/10.3390/toxins9100309 (2017).
doi: 10.3390/toxins9100309
pubmed: 28974033
pmcid: 5666356
Singh, P., Singh, M. K., Chauhan, V., Gupta, P. & Dhaked, R. K. Prevention of aggregation and autocatalysis for sustaining biological activity of recombinant BoNT/A-LC upon long-term storage. Protein Pept. Lett. 18, 1177–1187. https://doi.org/10.2174/092986611797642689 (2011).
doi: 10.2174/092986611797642689
pubmed: 21707522
Chauhan, R. et al. High level expression and immunochemical characterization of botulinum neurotoxin type F light chain. Protein Expr. Purif. 146, 51–60. https://doi.org/10.1016/j.pep.2018.01.014 (2018).
doi: 10.1016/j.pep.2018.01.014
pubmed: 29407166
Singh, B. R. Intimate details of the most poisonous poison. Nat. Struct. Biol. 7, 617–619. https://doi.org/10.1038/77900 (2000).
doi: 10.1038/77900
pubmed: 10932240
Patel, K. et al. A novel surface plasmon resonance biosensor for the rapid detection of botulinum neurotoxins. Biosensors. https://doi.org/10.3390/bios7030032 (2017).
doi: 10.3390/bios7030032
pubmed: 28783115
pmcid: 5618038
Black, R. E. & Gunn, R. A. Hypersensitivity reactions associated with botulinal antitoxin. Am. J. Med. 69, 567–570. https://doi.org/10.1016/0002-9343(80)90469-6 (1980).
doi: 10.1016/0002-9343(80)90469-6
pubmed: 7191633
Hibbs, R. G. et al. Experience with the use of an investigational F(ab’)2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin. Infect. Dis. 23, 337–340. https://doi.org/10.1093/clinids/23.2.337 (1996).
doi: 10.1093/clinids/23.2.337
pubmed: 8842274
Holley, J. L., Elmore, M., Mauchline, M., Minton, N. & Titball, R. W. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 19, 288–297. https://doi.org/10.1016/s0264-410x(00)00155-9 (2000).
doi: 10.1016/s0264-410x(00)00155-9
pubmed: 10930684
Ravichandran, E. et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75, 3043–3054. https://doi.org/10.1128/iai.01893-06 (2007).
doi: 10.1128/iai.01893-06
pubmed: 17371853
pmcid: 1932861
Takahashi, T. et al. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27, 2616–2624. https://doi.org/10.1016/j.vaccine.2009.02.051 (2009).
doi: 10.1016/j.vaccine.2009.02.051
pubmed: 19428868
pmcid: 2709450
Kiyatkin, N., Maksymowych, A. B. & Simpson, L. L. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 65, 4586–4591 (1997).
doi: 10.1128/IAI.65.11.4586-4591.1997
Chaddock, J. A. et al. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. 25, 219–228. https://doi.org/10.1016/s1046-5928(02)00002-5 (2002).
doi: 10.1016/s1046-5928(02)00002-5
pubmed: 12135553
Adekar, S. P. et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 3, e3023. https://doi.org/10.1371/journal.pone.0003023 (2008).
doi: 10.1371/journal.pone.0003023
pubmed: 18714390
pmcid: 2515629
Gilsdorf, J., Gul, N. & Smith, L. A. Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr. Purif. 46, 256–267. https://doi.org/10.1016/j.pep.2005.09.024 (2006).
doi: 10.1016/j.pep.2005.09.024
pubmed: 16297638
Agarwal, R., Eswaramoorthy, S., Kumaran, D., Dunn, J. J. & Swaminathan, S. Cloning, high level expression, purification, and crystallization of the full length Clostridium botulinum neurotoxin type E light chain. Protein Expr. Purif. 34, 95–102. https://doi.org/10.1016/j.pep.2003.10.017 (2004).
doi: 10.1016/j.pep.2003.10.017
pubmed: 14766304
Singh, M. K., Dhaked, R. K., Singh, P., Gupta, P. & Singh, L. Characterization of LC-HCC fusion protein of botulinum neurotoxin type A. Protein Pept. Lett. 18, 295–304. https://doi.org/10.2174/092986611794578314 (2011).
doi: 10.2174/092986611794578314
pubmed: 21054265
Derman, Y. et al. Neutralization of botulinum neurotoxin type E by a humanized antibody. Toxins. https://doi.org/10.3390/toxins8090257 (2016).
doi: 10.3390/toxins8090257
pubmed: 27626446
pmcid: 5037483
Chauhan, V., Chauhan, R., Sonkar, P. & Dhaked, R. K. Biochemical characterization of in vitro reconstituted biologically active recombinant shiga toxin. Protein Pept. Lett. 26, 227–234. https://doi.org/10.2174/0929866526666181228161834 (2019).
doi: 10.2174/0929866526666181228161834
pubmed: 30592251